- Submit Abstract
Geoff Green is CEO of Longeveron Inc. (Nasdaq: LGVN), a clinical-stage biotechnology company developing cell-based therapies for aging-related chronic diseases and conditions. Mr. Green’s career spans 25 years in a variety of leadership roles in public and private companies. Prior to Longeveron, he was VP, Operations at Partikula, VP, Business Development & Clinical Affairs at Accu-Break Pharmaceuticals, President/Acting CEO of DOR BioPharma (now Soligenix (NAS: SNGX)), VP, Business Development & Operations at Heart Genomics, and Director of Clinical Affairs at Innovative Drug Delivery Systems. Mr. Green received a B.A. in biology from Kenyon College, and an MBA from Barry University.